Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X0RI
|
|||
| Former ID |
DAP000505
|
|||
| Drug Name |
Mexiletine
|
|||
| Synonyms |
Mexiletene; Mexiletina; Mexiletinum; Mexilitine; Mexityl; Mexiletine HCL; KO1173; KO-1173; KOE-1173; Mexiletina [INN-Spanish]; Mexiletine (INN); Mexiletine [INN:BAN]; Mexiletinum [INN-Latin]; Mexitil (TN); (+-)-1-(2,6-dimethylphenoxy)propan-2-amine; (2RS)-1-(2,6-dimethylphenoxy)-2-aminopropane; 1-(2',6'-Dimethylphenoxy)-2-aminopropane; 1-(2,6-Dimethylphenoxy)-2-propanamine; 1-(2,6-dimethylphenoxy)propan-2-amine; 1-Methyl-2-(2,6-xylyloxy)ethylamine; 1-methyl-2-(2,6-xylyloxy)ethanamine; 2-(2-Aminopropoxy)-1,3-DiMethyl-Benzene Hydrochloride; 2-(2-aminopropoxy)-1,3-dimethylbenzene
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ventricular tachycardia [ICD-11: BC71; ICD-10: I47] | Approved | [1] | |
| Therapeutic Class |
Antiarrhythmic Agents
|
|||
| Company |
Boehringer Ingelheim
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H17NO
|
|||
| Canonical SMILES |
CC1=C(C(=CC=C1)C)OCC(C)N
|
|||
| InChI |
1S/C11H17NO/c1-8-5-4-6-9(2)11(8)13-7-10(3)12/h4-6,10H,7,12H2,1-3H3
|
|||
| InChIKey |
VLPIATFUUWWMKC-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 31828-71-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9429, 3249367, 5025145, 7979981, 8152616, 10518377, 11336009, 11361248, 11364496, 11367058, 11369620, 11371574, 11374409, 11377782, 11462220, 11466269, 11467389, 11485977, 11490543, 11492610, 11495416, 14772717, 29223284, 46505491, 47216821, 47291179, 47365237, 47662331, 47885459, 48110495, 48110496, 48259281, 49698949, 49969305, 50111148, 50111149, 50468461, 57322180, 85788456, 90341048, 92250812, 92729782, 96024903, 99233247, 103178542, 104010844, 104222091, 104305656, 117396020, 117396021
|
|||
| ChEBI ID |
CHEBI:6916
|
|||
| ADReCS Drug ID | BADD_D01452 ; BADD_D01453 | |||
| SuperDrug ATC ID |
C01BB02
|
|||
| SuperDrug CAS ID |
cas=031828714
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel alpha Nav1.5 (SCN5A) | Target Info | Blocker | [2] |
| KEGG Pathway | Adrenergic signaling in cardiomyocytes | |||
| Pathwhiz Pathway | Muscle/Heart Contraction | |||
| Reactome | Interaction between L1 and Ankyrins | |||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Cardiac Progenitor Differentiation | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.